Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · May 17, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the presence of circulating tumoral DNA (ctDNA) in the blood can help predict the risk of disease progression or relapse in patients with Waldenström Macroglobulinemia (WM) after they have completed the first six months of treatment. The goal is to see if checking for ctDNA at this point can provide valuable information about how a patient’s disease might behave in the following three years.

To participate in this trial, patients must be diagnosed with WM and receiving their first or later treatment for the disease. They should also be willing to give their consent to take part. The study is open to both men and women aged 65 to 74. Participants can expect to have their blood tested for ctDNA, and the results may help doctors make better decisions about their ongoing care. This trial is currently recruiting participants in the North-Western region, and it’s important to know that individuals with certain other types of cancers or specific conditions related to WM may not be eligible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with WM according to diagnostic criteria
• • Patients with WM followed in one of the centre of North-Western region.
• • Patients requiring first-line or subsequent-line therapy
• • Patients agreement for giving informed consent.
• • Social insurance system affiliation
• Exclusion Criteria:
• • Patients with another chronic B-cell malignancy
• • patients with other lymphoplasmacytic proliferations
• • patients with marginal zone lymphoma.
• • Patients with WM and histologic transformation
• • Absence of informed consent